scholarly journals HSP110 sustains chronic NF-κB signaling in activated B-cell diffuse large B-cell lymphoma through MyD88 stabilization

Blood ◽  
2018 ◽  
Vol 132 (5) ◽  
pp. 510-520 ◽  
Author(s):  
Christophe Boudesco ◽  
Els Verhoeyen ◽  
Laurent Martin ◽  
Catherine Chassagne-Clement ◽  
Leila Salmi ◽  
...  
Keyword(s):  
B Cell ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Large B Cell Lymphoma ◽  
Key Points ◽  
Large B Cell ◽  
In Cells

Key Points HSP110 sustains chronic NF-κB signaling in ABC-DLBCL through MyD88 stability. HSP110 is highly expressed in cells of patients with ABC-DLBCL and correlates with MyD88 expression.

scholarly journals B-cell–specific conditional expression of Myd88p.L252P leads to the development of diffuse large B-cell lymphoma in mice

Blood ◽  
2016 ◽  
Vol 127 (22) ◽  
pp. 2732-2741 ◽  
Author(s):  
Gero Knittel ◽  
Paul Liedgens ◽  
Darya Korovkina ◽  
Jens M. Seeger ◽  
Yussor Al-Baldawi ◽  
...  
Keyword(s):  
B Cell ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Specific Expression ◽  
Large B Cell Lymphoma ◽  
Key Points ◽  
Conditional Expression ◽  
Large B Cell

Key Points B-cell–specific expression of Myd88p.L252P leads to the development of DLBCL in mice. The Myd88p.L252P mutation cooperates with BCL2 amplifications in ABC-DLBCL lymphomagenesis in vivo.

scholarly journals Pathophysiological significance and therapeutic targeting of germinal center kinase in diffuse large B-cell lymphoma

Blood ◽  
2016 ◽  
Vol 128 (2) ◽  
pp. 239-248 ◽  
Author(s):  
Julie Marie Matthews ◽  
Shruti Bhatt ◽  
Matthew P. Patricelli ◽  
Tyzoon K. Nomanbhoy ◽  
Xiaoyu Jiang ◽  
...  
Keyword(s):  
B Cell ◽  
Germinal Center ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Therapeutic Targeting ◽  
Large B Cell Lymphoma ◽  
Key Points ◽  
Large B Cell

Key Points GCK signaling is activated in DLBCL, and this signaling is important to DLBCL proliferation and survival. Therapeutic targeting of GCK is feasible and may advance efforts to cure DLBCL patients.

scholarly journals Treatment factors affecting outcomes in HIV-associated non-Hodgkin lymphomas: a pooled analysis of 1546 patients

Blood ◽  
2013 ◽  
Vol 122 (19) ◽  
pp. 3251-3262 ◽  
Author(s):  
Stefan K. Barta ◽  
Xiaonan Xue ◽  
Dan Wang ◽  
Roni Tamari ◽  
Jeannette Y. Lee ◽  
...  
Keyword(s):  
Overall Survival ◽  
B Cell ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Pooled Analysis ◽  
Factors Affecting ◽  
Large B Cell Lymphoma ◽  
Key Points ◽  
Large B Cell

Key Points Rituximab use is associated with significant improvement in all outcomes for patients with HIV-associated CD20-positive lymphomas. Infusional EPOCH chemotherapy is associated with better overall survival in patients with AIDS-related diffuse large B-cell lymphoma (DLBCL).

scholarly journals UCH-L1 is induced in germinal center B cells and identifies patients with aggressive germinal center diffuse large B-cell lymphoma

Blood ◽  
2016 ◽  
Vol 127 (12) ◽  
pp. 1564-1574 ◽  
Author(s):  
Tibor Bedekovics ◽  
Sajjad Hussain ◽  
Andrew L. Feldman ◽  
Paul J. Galardy
Keyword(s):  
B Cell ◽  
Germinal Center ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Neuronal Marker ◽  
Large B Cell Lymphoma ◽  
Increased Risk ◽  
Key Points ◽  
Poor Outcomes ◽  
Large B Cell

Key Points The neuronal marker UCH-L1 is induced in, and specifically augments the oncogene-induced transformation of, GCB cells. High levels of UCHL1 identify patients with GC DLBCL with an increased risk for poor outcomes.

Genomic rearrangements involving programmed death ligands are recurrent in primary mediastinal large B-cell lymphoma

Blood ◽  
2014 ◽  
Vol 123 (13) ◽  
pp. 2062-2065 ◽  
Author(s):  
David D. W. Twa ◽  
Fong Chun Chan ◽  
Susana Ben-Neriah ◽  
Bruce W. Woolcock ◽  
Anja Mottok ◽  
...  
Keyword(s):  
B Cell ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Genomic Rearrangements ◽  
Large B Cell Lymphoma ◽  
Programmed Death ◽  
Key Points ◽  
Large B Cell

Key Points Programmed death ligands 1 and 2 are rearranged at a frequency of 20% in PMBCL.

scholarly journals High frequency of inactivating tetraspanin CD37 mutations in diffuse large B-cell lymphoma at immune-privileged sites

Blood ◽  
2019 ◽  
Vol 134 (12) ◽  
pp. 946-950 ◽  
Author(s):  
Suraya Elfrink ◽  
Charlotte M. de Winde ◽  
Michiel van den Brand ◽  
Madeleine Berendsen ◽  
Margaretha G. M. Roemer ◽  
...  
Keyword(s):  
B Cell ◽  
High Frequency ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Loss Of Function ◽  
Large B Cell Lymphoma ◽  
Key Points ◽  
Surface Localization ◽  
Cell Surface Localization ◽  
Large B Cell

Key Points Loss-of-function mutations in CD37 occur predominantly in diffuse large B-cell lymphoma at immune-privileged sites. CD37-mutated lymphoma B cells show impaired CD37 cell-surface localization, which may have implications for anti-CD37 therapies.

scholarly journals Analysis of FOXO1 mutations in diffuse large B-cell lymphoma

Blood ◽  
2013 ◽  
Vol 121 (18) ◽  
pp. 3666-3674 ◽  
Author(s):  
Diane L. Trinh ◽  
David W. Scott ◽  
Ryan D. Morin ◽  
Maria Mendez-Lago ◽  
Jianghong An ◽  
...  
Keyword(s):  
Dna Binding ◽  
B Cell ◽  
Cell Lymphoma ◽  
Phosphorylation Site ◽  
B Cell Lymphoma ◽  
Dna Binding Domain ◽  
Large B Cell Lymphoma ◽  
Key Points ◽  
Recurrent Mutations ◽  
Large B Cell

Key Points Recurrent mutations in FOXO1 affect the DNA binding domain and the T24 phosphorylation site, which disrupt interactions with 14-3-3. Presence of FOXO1 mutations is associated with decreased OS, particularly in DLBCL patients of the low-risk R-IPI categories.

scholarly journals R-CHOP 14 with or without radiotherapy in nonbulky limited-stage diffuse large B-cell lymphoma

Blood ◽  
2018 ◽  
Vol 131 (2) ◽  
pp. 174-181 ◽  
Author(s):  
Thierry Lamy ◽  
Gandhi Damaj ◽  
Pierre Soubeyran ◽  
Emmanuel Gyan ◽  
Guillaume Cartron ◽  
...  
Keyword(s):  
B Cell ◽  
Cell Lymphoma ◽  
Early Stage ◽  
B Cell Lymphoma ◽  
Limited Stage ◽  
Large B Cell Lymphoma ◽  
Key Points ◽  
Large B Cell

Key Points For early-stage DLBCL, R-CHOP alone is not inferior to R-CHOP followed by RT.

scholarly journals Socioeconomic disparities in mortality after diffuse large B-cell lymphoma in the modern treatment era

Blood ◽  
2014 ◽  
Vol 123 (23) ◽  
pp. 3553-3562 ◽  
Author(s):  
Li Tao ◽  
James M. Foran ◽  
Christina A. Clarke ◽  
Scarlett L. Gomez ◽  
Theresa H. M. Keegan
Keyword(s):  
B Cell ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Socioeconomic Disparities ◽  
Low Ses ◽  
Large B Cell Lymphoma ◽  
Key Points ◽  
Medicare Patients ◽  
Modern Treatment ◽  
Large B Cell

Key Points Patients living in low SES neighborhoods had worse survival after DLBCL. Disparity was most striking in younger (non-Medicare) patients and after the introduction of rituximab.

scholarly journals Diffuse large B-cell lymphoma genotyping on the liquid biopsy

Blood ◽  
2017 ◽  
Vol 129 (14) ◽  
pp. 1947-1957 ◽  
Author(s):  
Davide Rossi ◽  
Fary Diop ◽  
Elisa Spaccarotella ◽  
Sara Monti ◽  
Manuela Zanni ◽  
...  
Keyword(s):  
B Cell ◽  
Liquid Biopsy ◽  
Somatic Mutations ◽  
Cell Lymphoma ◽  
Clonal Evolution ◽  
B Cell Lymphoma ◽  
Large B Cell Lymphoma ◽  
Key Points ◽  
Diagnostic Biopsy ◽  
Large B Cell

Key Points Plasma cfDNA genotyping is as accurate as genotyping of the diagnostic biopsy in detecting clonal somatic mutations in DLBCL. Plasma cfDNA genotyping is a real-time, noninvasive tool that can be used to track clonal evolution in DLBCL.

Sign in / Sign up

Export Citation Format

Share Document